MorphoSys AG : MorphoSys Announces First Scientific Publication on Novel Antibody Platform Ylanthia

   MorphoSys AG : MorphoSys Announces First Scientific Publication on Novel
                          Antibody Platform Ylanthia

MorphoSys AG / MorphoSys Announces First Scientific Publication on Novel
Antibody Platform Ylanthia . Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.

MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX) announced today that a
first scientific  publication on  the  Company's novel,  proprietary  antibody 
platform Ylanthia was published  in the current issue  of "mAbs". The  article 
titled "A fully  synthetic human  Fab antibody  library based  on fixed  VH/VL 
framework pairings with  favorable biophysical properties"  describes for  the 
first time  the  detailed  design,  generation and  testing  of  the  Ylanthia 
library. Ylanthia became commercially available for existing and new  partners 
in 2012 and is currently used in two commercial agreements.

"Ylanthia sets new standards for  therapeutic antibody generation. Its  unique 
and innovative design translates into unprecedented structural diversity which
is expected to  result in  antibodies against  previously inaccessible  target 
molecules and covering  a unique  epitope space.  Furthermore, our  scientists 
introduced an entirely new concept to improve biophysical characteristics that
are relevant for antibody selection, manufacturing and administration, finally
leading to  better  drugs," commented  Dr.  Marlies Sproll,  Chief  Scientific 
Officer of MorphoSys AG.

To confirm the  functionality and  quality of the  Ylanthia antibody  library, 
phage selections against several antigens were performed. Subsequent  antibody 
characterization  revealed   broad   diversity  and   significantly   improved 
biophysical properties including  a very low  aggregation tendency,  increased 
thermodynamic stability and favorable solubility of Ylanthia antibodies.

Ylanthia comprises more  than 100  billion distinct,  fully human  antibodies, 
which makes it the industry's largest  known antibody Fab library. It uses  36 
fixed, naturally-occurring heavy and light chain framework combinations, which
translates  into  very   broad  structural   diversity.  Ylanthia's   antibody 
frameworks were pre-selected  for favorable expression  levels, stability  and 
aggregation behavior. A  shift towards higher  stability and stress  tolerance 
will increase shelf life and  serum stability of resulting antibody  products, 
making them more cost-effective to produce. A higher solubility in turn  opens 
up the path  for more  convenient ways of  administration, to  the benefit  of 
patients. When  needed, antibodies  from the  Ylanthia library  are  optimized 
using  MorphoSys's   proprietary  Slonomics   technology.  Slonomics   enables 
optimization of Ylanthia antibodies with unprecedented speed and flexibility.

The full paper is available on

About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 70 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few.
With its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys
is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular
updates about MorphoSys, visit

HuCAL^®, HuCAL  GOLD^®,  HuCAL PLATINUM^®,  CysDisplay^®,  RapMAT^®,  arYla^®, 
Ylanthia^® and  100 billion  high potentials^®  are registered  trademarks  of 
MorphoSys AG.

Slonomics^® is  a  registered  trademark  of  Sloning  BioTechnology  GmbH,  a 
subsidiary of MorphoSys AG.

This communication contains certain forward-looking statements concerning  the 
MorphoSys group of companies. The forward-looking statements contained  herein 
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties.  Should actual conditions  differ from the  Company's 
assumptions, actual results  and actions  may differ  from those  anticipated. 
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.

For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

Mario Brkulj
Associate Director Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

Alexandra Goller
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

Media Release (PDF)


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE

--- End of Message ---

MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany

WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
Press spacebar to pause and continue. Press esc to stop.